Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Peripheral Neuropathy With Type 2 Diabet...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Diabetic peripheral neuropathy is one of the most common and costly microvascular complications of diabetes impacting more than 50% of patients and costing more than 10.1 billion dollars annually. Intraneural Facilitation Therapy (INF® Therapy) is a non-invasive technique that has shown to improve balance and pain in patients with Type 2 Diabetic Peripheral Neuropathy (T2DPN); however, the underlying physiological mechanisms need further understanding. The purpose of this study is to investigate the physiological mechanisms behind two approaches to treating T2DPN, INF® Therapy and standard physical therapy. Eligible subjects presenting with diabetic neuropathy symptoms will be recruited and referred to the Loma Linda University Health's Neuropathic Therapy Center. Forty patients will be evenly randomized into two groups: an INF® Therapy Treatment group and standard physical therapy treatment group. Subjects will participate in 11 study visits over a period of 6 weeks. Non-invasive assessments will measure neuropathy pain, heart rate variability, neuropathy severity, blood oxygen levels, and blood flow under the skin. Lab draws will measure inflammation levels in the blood and how well blood sugar levels have been maintained over a period of about 3 months. Descriptive statistics and repeated measures ANOVA will be used to analyze data and answer the research questions. The findings of this study will provide a better understanding of how INF® Therapy and standard physical therapy work, subsequently improving non-invasive treatment methods for T2DPN patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Intraneural Facilitation Therapy Treatment — Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
  • Other: Standard Physical Therapy Treatment — The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.

Primary Outcomes

  • The Impact of INF® Therapy and Standard Physical Therapy on Heart Rate Variability (Through study completion, an average of 6 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-01-08
Completion: 2027-08-01
Eligibility
Age: 45 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Loma Linda University
Principal Investigators:
  • Mark Bussell, DPT, OCS (PRINCIPAL_INVESTIGATOR) - Loma Linda University Health
Contact Information
Study Contact:
Mark Bussell, DPT, OCS
909-558-6799
ntcresearch@llu.edu
Mark Bussell, DPT, OCS
909-558-6799
ntcresearch@llu.edu
Loma Linda University Health Neuropathic Therapy Center
Mark Bussell, DPT, OCS
Loma Linda University Health Neuropathic Therapy Center
Interventions
  • Other: Intraneural Facilitation Therapy Treatment — Intraneural Facilitation Therapy uses three manual holds to bias blood flow to closed endoneurial capillaries. The first is the facilitation hold, which is thought to pressurize the nervous system and bias circulation from the artery into the epineurium. This hold stretches the nerve further than the artery, increasing the amount of elastin in the artery and enlarging the opening of the arterial junction increasing blood into the epineurium. The secondary hold then increases epineurial blood into the transperineurial vessels increasing pressure into the endoneurial capillaries of the site being treated. The third hold, known as the sub hold, encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of Bernoulli's principle. The series of stretches will be repeated on the affected side for the treatment duration.
  • Other: Standard Physical Therapy Treatment — The standard physical therapy treatment includes muscle stretching, balance, and strengthening exercises known to improve neuropathy symptoms.
Study Locations (1 sites)
Loma Linda University Health Neuropathic Therapy Center, Loma Linda, California 92350 United States
Eligibility Criteria
Inclusion Criteria: * Between the ages of 45 and 85 * Moderate to severe type II diabetic neuropathy with one or more symptoms including: numbness, tingling, burning, sharp pain, and/or increased sensitivity. * Diagnosis confirmed by a physician. * Cellphone access with Android 5.0 and up or iOS 14.0 or later. Exclusion Criteria: Subjects with a medical condition predisposing them to medical decline during the next 6 months will be excluded from the study. Examples include: * Chemotherapy * Radiation * Lower extremity amputations * Open wounds * Documented active drug and or alcohol misuse * Chronic liver disease * Active inflammations * Other types of neuropathies not associated with diabetes including B12 deficiency and Charcot Marie Tooth * Morbid obesity * Pregnancy. * Taking beta blockers * Unable to maintain steady fingers or operate a cellphone * Smoking or ingesting marijuana * Having a pacemaker * Allergies to cobalt, chrome, or nickel
Conditions Obesity, Type 2 Diabetes
Phase PHASE1, PHASE2
Enrollment 188
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The trial will enroll healthy volunteers and individuals living with obesity, with and without Type 2 Diabetes. The study, with a treatment period of up to 16 weeks in selected cohorts, will investigate GUB-UCN2 as both a standalone therapy and on top of standard of care for obesity

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: GUB-UCN2 — GUB-UCN2 will be administered subcutaneously
  • Drug: Placebo — Placebo will be administered subcutaneously

Primary Outcomes

  • Number of Treatment Emergent Adverse Events (From baseline up to week 22)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-07-27
Completion: 2028-12
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 188 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gubra A/S
Contact Information
Study Contact:
Sr. Clinical Trial Manager
+45 3152 2650
drugdevelopment@gubra.dk
Interventions
  • Drug: GUB-UCN2 — GUB-UCN2 will be administered subcutaneously
  • Drug: Placebo — Placebo will be administered subcutaneously
Study Locations (1 sites)
PROFIL Institut fuer Stoffwechselforschung GmbH, Neuss, Germany
Eligibility Criteria
Inclusion Criteria: Part 1 * Signed and dated informed consent obtained before any trial-related activities * Males and female participants, aged between 18-55 years * Body Mass Index (BMI) between 20.0 and 29.9 kg/m\^2, inclusive * Considered generally healthy upon completion of medical history and screening safety assessments Part 2 * Signed and dated informed consent obtained before any trial-related activities * Male participants, aged between 18-55 years * Body Mass Index (BMI) between 30.0 and 35.0 kg/m\^2, inclusive Part 3 (participants with obesity) * Signed and dated informed consent obtained before any trial-related activities * Males and female participants, aged between 18-75 years * Body Mass Index (BMI) between 30.0 and 45.0 kg/m\^2 Part 3 (participants with T2D) * Signed and dated informed consent obtained before any trial-related activities * Male and female participants, aged between 18-75 years * Body Mass Index (BMI) between 27.0 and 35.0 kg/m\^2 * Diagnosed with type 2 diabetes mellitus, HbA1c ≤ 69.0 mmol/mol (≤ 8.5%) * Stable daily dose of antidiabetic medication Exclusion Criteria: * Known history of serious adverse reactions or serious hypersensitivity to drug or formulation excipients * Presence or history of clinically significant gastrointestinal, cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric, malignant, metabolic, endocrinological, hematologic or venereal disorder * Use or planned use of concomitant medication impacting the assessment of trial endpoints * Clinically significant abnormal laboratory parameters * Women of childbearing potential who are not using highly effective contraception
Conditions Type I Diabetes
Phase PHASE2
Enrollment 72
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: OPT101 — Subcutaneous injection.
  • Other: OPT101 Placebo to Match (PTM) — 5% Dextrose (w/v)

Primary Outcomes

  • Change in C-peptide (ng/mL) (48-week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-04-10
Completion: 2028-08-19
Eligibility
Age: 18 Years – 50 Years
Sex: ALL
Volunteers: false
Enrollment: 72 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Op-T LLC
Contact Information
Study Contact:
Lisa Boswell
303-503-9954
lb@op-t.com
Lisa Boswell
(303) 503-9954
lb@op-t.com
University of Alabama at Birmingham - Department of Medicina
Lisa Boswell
(303) 503-9954
lb@op-t.com
Diablo Clinical Research Center
Interventions
  • Drug: OPT101 — Subcutaneous injection.
  • Other: OPT101 Placebo to Match (PTM) — 5% Dextrose (w/v)
Study Locations (5 sites)
University of Alabama at Birmingham - Department of Medicina, Birmingham, Alabama 35294 United States
Diablo Clinical Research Center, Walnut Creek, California 94598 United States
Barbara Davis Center - University of Colorado Anschuttz Medical Campus, Aurora, Colorado 80045 United States
University of Chicago Medical Center, Chicago, Illinois 60637 United States
Rainier Clinical Research Center, Renton, Washington 98057 United States
Eligibility Criteria
Inclusion Criteria: * 1\. Able and willing and able to give informed consent for the trial (separate consent must be obtained for Parts B or C). 2\. Willing to wear a continuous glucose monitor for the duration of the trial (e.g., Freestyle Libre 3). 3\. Male or female aged ≥18 to 50 years on the day of signing informed consent. 4. Diagnosis of T1DM within the last 20 years for Part A, within 1 to 10 years \[N=15 at \>5 to 10, N=12 at 1 to 5 yrs\] for Part B, within less than or equal to 1 year for Part C. 5\. For Parts B and C only, T-cell phenotype Th40 level greater than or equal to 35% of CD3+ leukocytes (performed at the OPT lab). 6\. Is medically stable based on physical examination, medical history, laboratory results, and vital signs performed at screening. 7\. Women of childbearing potential (WOCBP) must have a negative highly sensitive serum test (beta- human chorionic gonadotropin) at screening and a negative urine pregnancy test at the Visit 1 Day 1 prior to receiving the investigational product. 8\. WOCBP must agree to use one of the following methods of birth control for the duration of the clinical trial: Systemic hormonal contraceptive (oral, injected, transdermal), intrauterine device, double barrier (e.g., cervical cap or diaphragm with condom or spermicide). Men with female partners must agree to use double barrier contraception, unless their partner is using systemic hormonal contraceptives or has an intrauterine device. Exclusion Criteria: * 1\. Current malignancy or history of malignancy other than basal cell carcinoma or squamous cell carcinoma in situ. 2\. Has an immune deficiency syndrome (for example, severe combined immunodeficiency syndrome, T-cell deficiency syndromes, B-cell deficiency syndromes, or chronic granulomatous disease), or bone marrow or organ transplantation, or a disease associated with lymphopenia. 3\. Has chronic kidney disease of Stage 2 or higher with eGFR of \<90 mL/min/1.73m2. 4\. Is currently receiving an immuno-modulatory treatment. 5. Patients with a history of venous and arterial thromboembolic events including, but not limited to, the following: 1. Deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke, transient ischemic attack, or arterial insufficiency causing digital gangrene. 2. Patients with recent immobilization or recent surgery. 3. Patients with a history of abnormal prothrombotic laboratories such as congenital or inherited deficiency of antithrombin III, protein C, protein S, or confirmed diagnosis of antiphospholipid syndrome. 6\. Has an active infections, is prone to infections or has chronic, recurrent or opportunistic infectious disease, including but not limited to, Epstein-Barr virus, cytomegalovirus, chronic renal infection, chronic chest infection, sinusitis, recurrent urinary tract infection, Pneumocystis carinii pneumonia, aspergillosis, latent or active granulomatous infection, histoplasmosis, or coccidioidomycosis or an open, draining, or infected non-healing skin wound or ulcer. 7\. Has recent or active hepatitis A infection, current/chronic hepatitis B and hepatitis C infection, or HIV infection. Participants with immunity to hepatitis B from previous infection, defined as negative HBsAg, positive anti-HBc, and positive hepatitis B surface antibody \[anti-HBs\] or vaccination \[defined as negative HBsAg, negative anti-HBc, and positive anti-HBs\] are eligible to participate. 8\. Has a history of latent or active tuberculosis. 9. Has received a live attenuated vaccine within the last 60 days including patients who plan to receive live attenuated vaccines during the study or within 60 days after the final dose of study treatment. 10\. Patients with the following should be excluded: <!-- --> 1. Abnormal coagulation test at screening: prothrombin time (PT; \>14 sec), activated partial thromboplastin time (aPTT; \>32 sec) or fibrinogen level (\<190 or \>450 mg/dL). 2. Abnormal liver function tests (except in the case of known Gilbert's syndrome): i. AST or ALT ≥3x ULN and total bilirubin ≥2x ULN ii. AST or ALT ≥5x ULN iii. Abnormal platelet counts (\<150 or \> 450 x10 to the third/uL) iv. Abnormal white blood cell counts (\< 3.0 or \>11.0 x10 to the third/uL ) v. Abnormal eGFR (\< 90 mL/min) vi. Abnormal Factor VIII (\<50% or \>150% of normal) vii. Abnormal D-Dimer (\> 500 ng/mL of fibrinogen equivalent units (FEU)) 11. Patients planning to undergo elective procedures or surgeries at any time after signing the ICF through the follow-up visit. 12\. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment. 13\. Recent history of bleeding or bleeding disorders or any condition whereby in the opinion of the treating investigator giving anti-coagulation during treatment would be contraindicated. 14\. History of hypersensitivity to antihistamines. 15. Body mass index \<20 or \>35 kg/M2 16. Patients with active drug or alcohol abuse within one year prior to screening or patients who test positive for required drug testing during screening (refer to §8.4). 17\. Patient is participating in a clinical trial of another investigational drug or device, including patients who have participated in another study for duration of 5 half-lives of the investigational agent. 18\. Patient is a prisoner. 19. Patients with any medical condition, including, but not limited to, cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, renal, or a psychiatric condition that, in the opinion of the Investigator, could compromise their ability to participate in this study.
Conditions Chronic Kidney Diseases, Albuminuria, Di...
Phase Not Applicable
Enrollment 300
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Kidney Biopsy — Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis

Primary Outcomes

  • Prevalence (From baseline to end inclusion (3 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-08-10
Completion: 2043-12-31
Eligibility
Age: 18 Years – 120 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Herlev Hospital
Collaborators: Copenhagen University Hospital, Rigshospitalet, Hillerod Hospital, Denmark, Zealand University Hospital, Holbaek Sygehus, Slagelse Sygehus, Nykøbing Falster County Hospital, Aarhus University Hospital, The Novo Nordisk Foundation Center for Basic Metabolic Research, Novo Nordisk A/S, Gubra ApS, Odense University Hospital, Aalborg University Hospital, Gødstrup Hospital, Steno Diabetes Center Copenhagen, Steno Diabetes Center Sjaelland, Steno Diabetes Center Nordjylland, Michigan Kidney Translational Medical Center
Principal Investigators:
  • Frederik Persson, MD, PhD (STUDY_CHAIR) - Steno Diabetes Center Copenhagen
Contact Information
Study Contact:
Marie Møller
+4561695364
marie.moeller@regionh.dk
Ditte Hansen
+4538682056
ditte.hansen.04@regionh.dk
Johan V Povlsen, MD, PhD
johan.povlsen@skejby.rm.dk
Aarhus Universitetshospital, Skejby
Interventions
  • Procedure: Kidney Biopsy — Harvesting of kidney tissue from people with type 2 diabetes and albuminuria for subsequent analysis
Study Locations (13 sites)
Aarhus Universitetshospital, Skejby, Skejby, Aarhus 8200 Denmark
Steno Diabetes Center Copenhagen, Copenhagen, Gentofte 2820 Denmark
Kristine D Schandorff, Hillerød, Hillerød 3400 Denmark
Holbæk Hospital, Holbæk, Holbæk 4300 Denmark
Rigshospitalet, Copenhagen, København Ø 2100 Denmark
Sjællands Universitetshospital, Køge, Køge, Køge 4600 Denmark
Nykøbing Falster Sygehus, Nykøbing Falster, Nykøbing F 4800 Denmark
Sjællands Universitetshospital, Roskilde, Roskilde, Roskilde 4000 Denmark
Slagelse Sygehus, Slagelse, Slagelse 4200 Denmark
Aalborg universitetshospital, Aalborg, Denmark
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Written informed consent * Diagnosis with T2DM according to the American diabetes Association (20) * eGFR \>30 mL/min/1.73 m2 (maximum six months old) * urine-albumin/creatinine-ratio (uACR) \> 700 mg/g or 24 hours urine albumin \>700 mg on more than one measurement Exclusion Criteria: * Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy * Factors that increases the risk of complications due to kidney biopsy: * Hemoglobin \< 6 mmol/L * INR \>1,4 at the time for biopsy * Platelet count \< 100 x 109/l * Uncontrolled high blood pressure (defined as systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg) * Only one functioning kidney * Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy * Multiple bilateral kidney cysts * Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy * Unwilling to receive blood transfusion * Unable to lie flat in bed six hours after biopsy * Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines * Unable to understand written and oral information * Kidney transplant recipient * Previous medical kidney biopsy * Women who are pregnant or planning to become pregnant before the kidney biopsy is performed * Treatment with Marcoumar (all other anticoagulants are accepted) * High thromboembolic risk combined with held in anticoagulation therapy according to the report "Perioperative regulation of antithrombotic treatment" (PRAB) (22) * mechanical heart valve * atrial fibrillation AND CHA2DS2-VASc\> 5 and/or stroke within the last three months * recurrent venous thromboembolism OR venous thromboembolism within the last three months * less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG)) * less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES)) * less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis) * less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG) * less than 3 months after revascularization in individuals with stable CAD (PCI with DES) * less than 3 months after stroke, or Transient Ischemic Attack (TIA) * Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy If a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation.

China Monogenic Diabetes Registry

NCT07492004
Recruiting
Conditions Neonatal Diabetes, Monogenic Diabetes, M...
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to establish a digital registry, screening platform for patients with monogenic diabetes using internet-based and mobile application technologies. The primary objectives are to: Characterize the genetic landscape of monogenic diabetes in the Chinese population, including pathogenic variants and their distribution Participants will: * Enroll in the monogenic diabetes registry via mobile application or web-based platform * Undergo molecular genetic testing to establish a definitive diagnosis

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No Interventions — No Interventions

Primary Outcomes

  • Screened and confirmed monogenic diabetes (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-02-28
Completion: 2030-07-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tianjin Medical University General Hospital
Contact Information
Study Contact:
Ming Liu
+86 022-27813550
mingliu@tmu.edu.cn
Hua Shu
+86 15010106182
shuhuawelcome@163.com
Ming Liu
+86 022-27813550
mingliu@tmu.edu.cn
Tianjin medical university general hospital
Interventions
  • Other: No Interventions — No Interventions
Study Locations (1 sites)
Tianjin medical university general hospital, Tianjin, 300052 China
Eligibility Criteria
Inclusion Criteria: 1. Diabetes diagnosed before 25 years of age; OR diabetes diagnosed before 35 years of age with ≥1 first-degree relative (parent, sibling, or offspring) diagnosed with diabetes before 40 years of age 2. Body mass index (BMI) at diagnosis 28 kg/m² 3. Negative glutamic acid decarboxylase antibody (GAD-Ab) Exclusion Criteria: 1. Secondary diabetes 2. Active malignancy or history of malignant tumor within the past 5 years
Conditions Asthmatic Patients, MDI, Aerosol Generat...
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

* The goal of this clinical trial is to evaluate the performance, feasibility, and safety of emergency spacers compared to traditional spacers for the delivery of aerosolized drugs using pMDI. in young children and adult asthmatic patients The main questions it aims to answer are: 1. Measuring total emitted dose emitted from pMDI alone and attached to spacers. 2. Determining the pharmacokinetic parameter of aerosol delivered by different spacers. 3. Determining the lung bioavailability of aerosol delivered by different spacers. 4. Determining the systemic bioavailability of aerosol delivered by different spacers. 5. Determining the lung function after aerosol delivered by different spacers. 6. Determining the safety Researchers will compare salbutamol amount delivered using pMDI alone and pMDI connected to differents spacers to evaluate the performance, feasibility, and safety of emergency spacers compared to traditional spacers for the delivery of aerosolized drugs. Participants will asked to * inhale salbutamol through pMDI alone and pMDI connected to different spacers * perform lung function test using spirometer * urine samples will be taken from patients 30 minutes and 24 hours after dose inhalation. * use pulse oximeter to measure heart rate

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI alone — patients use ventoline pMDI alone
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to plastic juice cup spacer
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer — patient use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the DispozABLE spacer
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to the Lite-Aire collapsible valved holding chamber spacer

Primary Outcomes

  • the total emitted dose (3 months)
  • Mass median aerodynamic diameter (MMAD) (3 months)
  • fine particle dose (FPD) (3 months)
  • fine particle fraction (FPF) (3 months)
  • lung bioavailability (4 months)
  • systemic bioavailability (4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-11-01
Completion: 2025-02-10
Eligibility
Age: 6 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beni-Suef University
Principal Investigators:
  • Mohamed Emam Abdelrahim, professor (STUDY_CHAIR) - Beni-Suef
  • Haitham Saeed Abdel-Azeez, Associate professor (STUDY_DIRECTOR) - Beni-Suef
  • Nabila Ibrahim Abdel Mageed Laz, professor (STUDY_DIRECTOR) - Beni-Suef
Contact Information
Study Contact:
Omar Ahmed Sayed, Demonstrator
+201152677683
OmarAhmed@pharm.bsu.edu.eg
Omar Ahmed Sayed, Demonstrator
+201090313474
omarahmedsayed1111@gmail.com
university hospital, manager
022319397 - 02317953
doaamahmoud@med.bsu.edu.eg
Beni-Suef university hospital
Interventions
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI alone — patients use ventoline pMDI alone
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Able spacer
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connectec to Tips-Haler spacer
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Aerochamber plus flow vu valved holding chamber
  • Drug: Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer — patients use Ventoline® Evohaler® 100 µg/inhalation pMDI connected to Atomizer chamber spacer
Study Locations (1 sites)
Beni-Suef university hospital, Banī Suwayf, Egypt Egypt
Eligibility Criteria
Inclusion Criteria: • Mild and moderate asthmatic patients aged from 6 - 80 year old. Exclusion Criteria: * Severe asthmatics or patients admitted to an intensive care unit * ischemic heart disease * recent abdominal surgery * inability to perform properly the pulmonary function tests * hepatic or renal impairment * hypersensitivity to salbutamol.
Conditions Asthma
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the site and mechanisms responsible for expiratory airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to severe persistent expiratory airflow obstruction. Treatment will include inhaled corticosteroids and long acting beta2agonists and long acting muscarinic antagonists. We are interested in determining whether the large and/or small airways are the predominant site of airflow limitation. We are also interested in determining whether intrinsic small airways obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow limitation and to what extent may be attributed to loss of lung elastic recoil vs decreased airway conductance in peripheral airways. We are also interested to evaluate the role of varying doses of inhaled corticosteroids to suppress large and small airway inflammation using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes, spirometry and measurements of exhaled nitric oxide will also be obtained if possible during a naturally occurring exacerbation of asthma. High resolution thin section CT of the lung will also be obtained. Analysis will evaluate integrity of the lung parenchyma as to absence and or presence of emphysema and extent of emphysema using voxel quantification. We will also investigate optical coherence tomography to detect clinically unsuspected emphysema. We will also obtain autopsy material when available in asthmatics who expire. Will also measure serum periostin as a marker of inflammation by collaborating with Genetech in San Francisco.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Drug: budesonide/formoterol — 2 inhalations 2X/daily in treated arm/group. No placebo group
  • Drug: fluticasone/salmeterol — fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
  • Drug: mometasone/formoterol — 200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in no placebo group
  • Drug: Prednisone — 0-15 mg daily as needed

Primary Outcomes

  • use exhaled nitric oxide as a surrogate marker of large airway vs small airway/lung inflammation following various doses of inhaled corticosteroids (20-60 days)
  • determine site of airflow limitation, whether predominantly large and /or small airways using expiratory flow volume curves obtained before and after asthmatics breathe a 80% helium-20% oxygen gas mixture (20-60 days)
  • investigate the mechanisms that limit expiratory airflow: intrinsic airway obstruction vs loss of lung elastic recoil (20-60 days)
  • determine the extent of asthma and distribution of emphysema (within 10 days following death or explanted lung if lung transplant obtained)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2007-10-25
Completion: 2027-06
Eligibility
Age: 10 Years – 95 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Gelb, Arthur F., M.D.
Principal Investigators:
  • Arthur F Gelb, MD (PRINCIPAL_INVESTIGATOR) - Arthur F Gelb Medical Corporation
Contact Information
Study Contact:
Arthur F Gelb, MD
562-633-2204
afgelb@msn.com
Arthur F Gelb, MD
Arthur F Gelb Medical Corporation
Interventions
  • Drug: budesonide/formoterol — 2 inhalations 2X/daily in treated arm/group. No placebo group
  • Drug: fluticasone/salmeterol — fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
  • Drug: mometasone/formoterol — 200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in no placebo group
  • Drug: Prednisone — 0-15 mg daily as needed
Study Locations (1 sites)
Arthur F Gelb Medical Corporation, Lakewood, California 90712 United States
Eligibility Criteria
Inclusion Criteria: * Current non-smoking (\<10 pack yr smoking history) * Stable, treated asthmatics * Age 12-95 yr * post 180ug albuterol by MDI: FEV 1/FVC \< 70% and FEV 1 \<80% predicted Exclusion Criteria: * Pregnancy
Conditions Severe Asthma
Phase NA
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This study will investigate whether a structured physical activity promotion programme, delivered alongside standard treatment with tezepelumab, increases objectively measured physical activity and the proportion of adults with severe asthma achieving clinical remission compared with standard care alone. Although biologic therapies have improved asthma control for many people with severe asthma, many individuals remain physically inactive, experience reduced exercise tolerance, and continue to report symptoms that affect their quality of life. Physical inactivity may represent a modifiable factor that limits the achievement of optimal health outcomes. Adults with severe asthma who are starting tezepelumab as part of routine clinical care will be randomly assigned to receive either standard care alone or standard care plus a 12-week physical activity promotion programme. The programme includes an individual consultation, group behavioural support sessions, personalised goal setting, self-monitoring using a smartphone application, and strategies to help participants increase and maintain their physical activity levels. Participants will be followed for 12 months. The study will primarily assess change in objectively measured daily step count after 3 months. The primary clinical outcome will be the proportion of participants achieving clinical remission after 12 months. Additional outcomes include asthma disease stability, asthma exacerbations, objectively measured physical activity at 12 months and functional exercise capacity. The findings will help determine whether combining physical activity promotion with biologic therapy improves outcomes for adults with severe asthma and could inform future models of routine severe asthma care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Physical activity promotion — A 12-week structured physical activity promotion programme delivered alongside standard care for severe asthma. The intervention comprises an individual behavioural consultation followed by six online group support sessions delivered every two weeks. It incorporates evidence-based behaviour change techniques, including personalised goal setting, action planning, self-monitoring using the Active10 smartphone application, feedback, problem solving, and relapse prevention, informed by the Capability, Opportunity, Motivation-Behaviour (COM-B) framework to support sustained increases in daily physical activity.
  • Drug: Tezepelumab — Tezepelumab administered according to the licensed prescribing information and routine clinical practice for the treatment of severe asthma. All participants receive tezepelumab as standard care throughout the study.

Primary Outcomes

  • Daily step count (Baseline to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-31
Completion: 2029-12-01
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Leeds
Collaborators: Hull University Teaching Hospitals NHS Trust, Bradford Institute for Health Research, Mid Yorkshire Teaching NHS Trust, Sheffield Teaching Hospitals NHS Foundation Trust
Contact Information
Study Contact:
Oliver J Price, PhD
+44(0)113 343 2909
o.price1@leeds.ac.uk
Ian J Clifton, MD
i.clifton@nhs.net
Oliver J Price, PhD
o.price1@leeds.ac.uk
Leeds Teaching Hospitals NHS Trust
Interventions
  • Behavioral: Physical activity promotion — A 12-week structured physical activity promotion programme delivered alongside standard care for severe asthma. The intervention comprises an individual behavioural consultation followed by six online group support sessions delivered every two weeks. It incorporates evidence-based behaviour change techniques, including personalised goal setting, action planning, self-monitoring using the Active10 smartphone application, feedback, problem solving, and relapse prevention, informed by the Capability, Opportunity, Motivation-Behaviour (COM-B) framework to support sustained increases in daily physical activity.
  • Drug: Tezepelumab — Tezepelumab administered according to the licensed prescribing information and routine clinical practice for the treatment of severe asthma. All participants receive tezepelumab as standard care throughout the study.
Study Locations (1 sites)
Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF United Kingdom
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-70 years. * Physician-diagnosed severe asthma. * Eligible for tezepelumab according to NICE TA880. * History of ≥3 asthma exacerbations requiring oral corticosteroids in the previous 12 months or receiving maintenance oral corticosteroid therapy. * Objective confirmation of asthma, including bronchodilator reversibility, bronchial hyperresponsiveness and/or variable airflow obstruction, as part of routine clinical assessment. * Decision to commence tezepelumab made by the treating multidisciplinary severe asthma team prior to study enrolment. * Able and willing to provide written informed consent. Exclusion Criteria: * Non-asthma respiratory disease that may confound study outcomes (e.g. obstructive sleep apnoea). * Pregnancy. * Significant non-asthma medical conditions likely to impair physical activity or functional exercise capacity (e.g. acute musculoskeletal injury). * Any condition that, in the opinion of the investigator, would make participation unsafe or compromise study completion.
Conditions Chronic Obstructive Pulmonary Disease
Phase Not Applicable
Enrollment 1000
Locations 36 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to collect empirical data that elucidates the clinical profile and therapeutic efficacy of benralizumab among the patients aged 12 years and above, with severe eosinophilic asthma. The study will focus on the early treatment response, treatment outcomes and the change in asthma control of benralizumab therapy in a real-world setting in China. This study will also describe the physician-reported reasons for discontinuation and switching of benralizumab therapy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: benralizumab — non-interventional

Primary Outcomes

  • asthma control questionnaire (Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-11
Completion: 2028-01-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Principal Investigators:
  • chen wang, PhD (PRINCIPAL_INVESTIGATOR) - China-Japan Friendship Hospital
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Other: benralizumab — non-interventional
Study Locations (36 sites)
Research Site, Anhui, China
Research Site, Anning, China
Research Site, Beijing, China
Research Site, Binzhou, China
Research Site, Changzhou, China
Research Site, Fenyang, China
Research Site, Guangdong, China
Research Site, Guangzhou, China
Research Site, Hangzhou, China
Research Site, Huzhou, China
Eligibility Criteria
Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply: * Patients must to be 12 years old (inclusive) at the time of signing the informed consent. * Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician. * Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent. * Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures. Exclusion criteria -Patients should not enter the study if any of the following exclusion criteria are fulfilled: * Patients currently participating in any other clinical trial. * Known history of allergy or reaction to any component of the study treatment formulation. * Malignancy of any kind. * Patients with prior or ongoing treatment with benralizumab.
Conditions Asthma
Phase Not Applicable
Enrollment 74
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases. The primary outcome of this study will be changes in airway hyperresponsiveness to methacholine challenge reported as response-dose-ratio before and after initiation of anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for measuring changes in FEV1 and Airwave oscillometry. A reduced degree of airway hyperreactivity and airway resistance after initiating ani-IL-17 could indicate effectiveness of anti-IL-17 in asthma patients which would have to be examined further in a population of asthma patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Airway hyperresponsiveness (approximately 4 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-08-02
Completion: 2027-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 74 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Copenhagen University Hospital, Hvidovre
Principal Investigators:
  • Jonas A Baekdal, MD (PRINCIPAL_INVESTIGATOR) - University hospital, Hvidovre
Contact Information
Study Contact:
Jonas A Baekdal, MD
+45 60134687
jonas.aggerholm.baekdal.02@regionh.dk
jonas A Baekdal, MD
+4523497817
jonas.aggerholm.baekdal.02@regionh.dk
Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University Hospital
Interventions
N/A
Study Locations (1 sites)
Respiratory Research Unit Hvidovre Department of Respiratory Medicine, Copenhagen University Hospital, Hvidovre, Capital Region 2650 Denmark
Eligibility Criteria
Inclusion Criteria: * Patients planning to start treatment with anti-IL-17 antibodies Exclusion Criteria: * Current pregnancy * FEV1 \< 1.5L or less than 60% of predicted value expected. * Previous anaphylactic shock or severe allergic reaction to medicine * Uncontrolled hypertension * Myocardial infarction or stroke within the last 3 months * Known aortic aneurysm * Recent eye surgery or risk of elevated intracranial pressure * Treatment with systemic corticosteroids within 6 weeks
Conditions Asthma
Phase Not Applicable
Enrollment 355
Locations 21 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese Population

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Descriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables. (At baseline)
  • Descriptive summary of biomarker level. (At baseline)
  • Statistical clustering of key biomarkers. (At baseline)
  • FEV1 level (At baseline)
  • Forced Vital Capacity (FVC) (At baseline)
  • Maximal Mid Expiratory Flow (MMEF) (At baseline)
  • Airway remodeling (At baseline)
  • Gas trapping (At baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-08
Completion: 2026-10-08
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 355 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (21 sites)
Research Site, Chengdu, Sichuan China
Research Site, Beijing, China
Research Site, Changsha, China
Research Site, Dongguan, China
Research Site, Foshan, China
Research Site, Guangzhou, China
Research Site, Hainan, China
Research Site, Hohhot, China
Research Site, Huizhou, China
Research Site, Kunming, China
Eligibility Criteria
Inclusion Criteria: * Age 18 to 75 years of age * acceptable FEV1 (according to ATS and ERS) * compliance with study procedures All Asthma Cohorts * physician diagnosed Asthma greater or equal to 3 months prior to screening visit Exclusion Criteria: * history of alcohol or drug abuse within the past year * pregnant at time of an assessment * has an altered mental status at the time of informed consent * receipt marketed or investigational biologic(s) within 3 months or 5 half-lives prior to visit 1, whichever is longer * history or current upper or lower respiratory infection or symptoms within 2 weeks of baseline assessments * terminal diseases and/or organ failure or participants otherwise considered not appropriate for the study participation * Receipt LTRAs or 5-lipoxygenase (5-LO) inhibitors (eg zileuton and montelukast) within 1 month or 5 half-lives prior to baseline, whichever is longer.
Conditions Smoking Reduction, Asthma in Children, W...
Phase NA
Enrollment 160
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-28
Study Details Design, interventions, and primary outcomes

About This Study

Unrestricted parental smoking habits are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of non-communicable diseases (NCDs). Exposure to secondhand tobacco smoke in early life contributes to the development of specific NCDs in children, i.e. asthma. Early preventive measures to improve lifestyle behavior in parents are therefore of utmost importance. The aim of ELIPSE-II is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering levels of urinary cotinine as a measure of second-hand smoke exposure in their children .

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Life-Style app — The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
  • Other: Sham Comparator — The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.

Primary Outcomes

  • Change from baseline in urinary levels of cotinine in children (At 22 weeks after baseline (Post intervention))
  • Change from baseline in urinary levels of cotinine in children (At 48 weeks after baseline (Follow-Up))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-05-07
Completion: 2028-12-31
Eligibility
Age: Up to 5 Years
Sex: ALL
Volunteers: true
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insel Gruppe AG, University Hospital Bern
Collaborators: University of Bern
Principal Investigators:
  • Matthias V. Kopp, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland
  • Michael Kaess, Prof. Dr. (PRINCIPAL_INVESTIGATOR) - Universitäre Psychiatrische Dienste Bern (UPD), University of Bern, Switzerland
Contact Information
Study Contact:
Matthias V. Kopp, Prof. Dr.
+41 31 66 4 13 51
matthias.kopp@insel.ch
Julian Jakob, Dr.
+41 31 632 12 93
julian.jakob@insel.ch
Julian Jakob, MD
+41 31 632 12 93
julian.jakob@insel.ch
Department of Paediatrics, Inselspital, Bern University Hospital
Interventions
  • Behavioral: Life-Style app — The modules of the Life-Style app are introduced and unlocked sequentially during the first weeks of the intervention phase. Afterwards the modules are fully available. Duration and frequency of app-use is not limited. The parents are accompanied by a coach through the app, who gives regular structured feedback and individual inputs. The coach has access to all data collected in the app.
  • Other: Sham Comparator — The parents get a flyer with information on second-hand smoke exposure and references to smoking cessation programs, and do not have an active app during the main intervention period.
Study Locations (1 sites)
Department of Paediatrics, Inselspital, Bern University Hospital, Bern, 3010 Switzerland
Eligibility Criteria
Inclusion Criteria: * Age: younger than 6 years * Exposed to second-hand smoke at home (at least one parent smoking) * German speaking parent * All sex and ethnic backgrounds * Signed informed consent form from parent * Children live/grow-up in the same household as the parental participant * Referred by a health care professional (e.g. physician, midwife, nurse, other professions) Exclusion Criteria: * Participation in another study/trial targeting similar outcomes * Participation in an active smoking cessation programme